Skip to main content
  • Policy
    Get Involved
    Join BIOAction
    View Advocacy Toolkit
    Patient Advocacy
    Human Health
    Cost and Value of Biopharmaceuticals
    Antimicrobial Resistance
    Vaccines & Biodefense
    Drug Development & Review
    International
    Global Markets & Trade
    Multilateral Organizations
    Intellectual Property
    All Policy
    Patient Advocacy

    Join BIO as we champion for bringing new treatments to patients with serious medical conditions and to support policies that promote innovation and improve patient access.

  • Member
    Membership Options
    Become a BIO Member
    Member Directory
    Have a Voice
    Membership Eligibility
    Member Toolkit
    Benefits By Sector
    member health
    Human Health
    member startups
    Startups
    member non R&D
    Non-R&D Companies
    Member Savings
    BBS-Programs-vwr
    VWR, Part of Avantor
    75% off Lab Supplies
    Save with BIO
    Save with BIO
  • News & Insights
    Latest biotech news
    Popular blogs
    Events
    Policy
    BIO Statements
    Press Releases
    Letters, Testimony & Comments
    Amicus Briefs
    BIO Reports
    Industry Analysis Reports
    Biotech Jobs
    Economic Development Best Practices
    BIO Briefly
    Issue Briefs
    BIO.News
    I am BIO Podcast
    All News & Insights

    Sign up for the BIO.News Newsletter >

  • Events
    Event Portfolio
    Business Development
    Health
    International
    Professional Development
    Members Only
    All Events
    BIO International Convention

    June 22-25, 2026 | San Diego, CA

    Learn More
    BIO Asia-Taiwan
    BIO Europe

    November 3-5, 2025
    Vienna, Austria

    BIO Investor Forum
    Partnering @JPM Week

    January 12-15, 2026
    San Francisco, CA

    BIO Patient & Health Advocacy Summit
    BIO Investment & Growth Summit

    March 2-3, 2026
    Miami, FL

    BIO Webinars

    Explore the webinar opportunities for interactive, online learning about emerging issues in biotechnology public policy, scientific progress, and raising capital, plus methods to benefit from BIO’s membership services.

  • About
    About Us
    Learn about our priorities
    BIO Leadership
    Meet BIO's Senior Leadership and Board of Directors
    Biotech Basics
    Read about biotechnology
    Industry Recognition
    Get to know the outstanding people and companies BIO supports
    Careers @ BIO
    Explore job openings with BIO today
    Diversity & Inclusion >

    Our tools and initiatives on workforce development, diversity and inclusion are designed to advance a more globally competitive industry.

  • Resource Hub
    Latest Resources
    BIO Early-Stage Resources Hub
    BIO Professional Development
    BIO Content Hub
    Biotech News (BIO.News)
    BIO.News Newsletter
    I am BIO Podcast
    BIO Advocacy Toolkit
    Resources Hub
    BIO Early-Stage Resources Hub
    BIO Professional Development
    BIO Webinars
    BIO Microsites
    Clinical Trials: The Power of Participation
    Covid Vaccine Facts
  • Search Results
    Previously Searched
Logo
Logo
Home
Search
  • Policy
    Human HealthPatient AdvocacyInternationalIntellectual PropertyAll Policies
  • Member
    Become a BIO MemberBenefits By Sector
    Human HealthStartupsNon-R&D Companies
    Member DirectoryHave a VoiceMembership EligibilitySavings
  • News & Insights
    Press ReleasesBio.News BlogLetters, Testimony & CommentsAmicus BriefsIndustry Analysis ReportsBiotech JobsEconomic Development Best PracticesIssue BriefsBIO.NewsVideosAll News & Insights
  • Events
    BIO International ConventionBIO Asia-TaiwanAll Events
  • About
    About UsBIO LeadershipDiversity & InclusionBiotech BasicsIndustry RecognitionCareers @ BIO
  • Resource Hub
    Biotech News (BIO.News)BIO.News NewsletterI am BIO PodcastBIO Advocacy ToolkitBIO Early-Stage Resources HubBIO Professional DevelopmentBIO WebinarsClinical Trials: The Power of ParticipationCovid Vaccine Facts
Search Results
Previously Searched
Search Results
Previously Searched
3104 results found
Expand All
Apply All
3104 results found

How biotech can lead us to a plastic-free future
Share
Good Day BIO Newsletter  •  March 5, 2020
There’s more news today on the coronavirus response, including what to expect from the emergency funding package as well as a new partnership between two BIO members, Vir and Alnylam. Be sure to check back tomorrow for more details. In the meantime, we’ve got a recap of yesterday’s hearing on how to address the plastic waste crisis, as well as more on the CAR T-cell payment problem, in about 800 words, just under 4 minutes.
Read More

The coronavirus is no match for science—but we must finish the job
Share
Good Day BIO Newsletter  •  March 4, 2020
We’re halfway through the week. Today, BIO CEO Jim Greenwood published a must-read op-ed in Morning Consult about the industry’s coronavirus response. We’re also looking at why biotech is key to a healthy diet, and the latest coronavirus news from Capitol Hill, in 815 words, or about 4 minutes.
Read More

The coronavirus is no match for science—but we must finish the job
Share
Good Day BIO Newsletter  •  March 4, 2020
We’re halfway through the week. Today, BIO CEO Jim Greenwood published a must-read op-ed in Morning Consult about the industry’s coronavirus response. We’re also looking at why biotech is key to a healthy diet, and the latest coronavirus news from Capitol Hill, in 815 words, or about 4 minutes.
Read More

Gilead expands trials on promising antiviral in coronavirus fight
Share
Good Day BIO Newsletter  •  March 2, 2020
What was more shocking: the South Carolina primary and how it changed the Democratic race just days ahead of Super Tuesday, or Trump’s third-ever appearance in the press briefing room on Saturday? Tweet us your thoughts at @IAmBiotech. The coronavirus continues to dominate the news today. BIO member companies are in town to join President Trump at the White House to discuss efforts to contain the outbreak, and Vice President Pence will close the day with a media briefing at 5:00 PM. Keep an eye out for a “Special Edition” of Good Day BIO with breaking news from the day, depending on what we learn.We’ve also got an update on the animal biotechnology “turf war” between the USDA and FDA, in about 870 words, or 4 minutes, 20 seconds.
Read More

Gilead expands trials on promising antiviral in coronavirus fight
Share
Good Day BIO Newsletter  •  March 2, 2020
What was more shocking: the South Carolina primary and how it changed the Democratic race just days ahead of Super Tuesday, or Trump’s third-ever appearance in the press briefing room on Saturday? Tweet us your thoughts at @IAmBiotech. The coronavirus continues to dominate the news today. BIO member companies are in town to join President Trump at the White House to discuss efforts to contain the outbreak, and Vice President Pence will close the day with a media briefing at 5:00 PM. Keep an eye out for a “Special Edition” of Good Day BIO with breaking news from the day, depending on what we learn.We’ve also got an update on the animal biotechnology “turf war” between the USDA and FDA, in about 870 words, or 4 minutes, 20 seconds.
Read More

Coronavirus, Rare Disease Day, and biofuels – who's ready for the weekend?
Share
Good Day BIO Newsletter  •  February 28, 2020
We’re closing a crazy week with a recap of all the coronavirus and biofuels news you might have missed, plus a reminder about Rare Disease Day (tomorrow) and why we need to protect the Orphan Drug Act, in about 760 words, just under 4 minutes.  Enjoy the weekend. Don’t panic. Wash your hands.
Read More

The U.S. has a little beef with Europe
Share
Good Day BIO Newsletter  •  February 27, 2020
If you missed President Trump’s press conference yesterday on the COVID-19 coronavirus, here’s a recap and video, plus details on the announcement that Vice President Mike Pence will lead a task force to combat the spread and background on how this all happened. But, believe it or not, #coronavirus is not the only news today. We’ve got the details on a new request regarding coverage for CAR T immunotherapy, as well as why the U.S. has beef with the EU over agriculture trade, in about 830 words, or 4 minutes.
Read More

United States’ drug development leadership is under attack
Share
Good Day BIO Newsletter  •  February 26, 2020
Last night, the Democratic presidential candidates DID talk about health care during the debate in South Carolina—and specifically called out President Trump for his coronavirus response. At least they agree on something, right? What do you think about the presidential race and the coronavirus response? Tweet us your takes at @IAmBiotech. Today, we have news about BIO member Cargill launching plant-based “meat” and an important opinion piece on how policy could harm drug innovation in the United States, in about 825 words, or 4 minutes.
Read More

Governors Letter to President Trump on Animal Biotechnology
Share
Agriculture & Environment, Food & Farm Innovation  •  Letters, Testimony & Comments  •  February 25, 2020
We the undersigned Governors would like to draw your attention to an important issue facing U.S. agriculture. Farmer access to new biotechnologies, such as gene editing, is critical to maintaining the security and stability of the rural economy and our nation’s food supply. These technologies offer significant promise to enhance the health of animals and plants, make better use of agricultural resources, and produce safer food. This potential can only be realized with appropriate, science-based regulation at the federal level. We ask that you move all agricultural applications of biotechnology in animals under the regulatory authority of the USDA. As plant applications are regulated under the Plant Protection Act, so too should agricultural animal applications be regulated under the Animal Health Protection Act. Not only will a common policy under the USDA better foster development of this technology for the public good, it will also far better serve U.S. interests in marketing our agricultural products overseas. The current situation—having significantly different regulatory approaches under different agencies for plants and animals—is simply not tenable. The U.S. agriculture sector is vital to the American economy, generating over $1 trillion in annual economic activity. The continued success of American agriculture depends on access to new biotechnology that has been well-vetted under a rational, science-based regulatory system administered by the USDA. We appreciate your attention to this matter.
Read More

The first coronavirus vaccine is ready for testing
Share
Good Day BIO Newsletter  •  February 25, 2020
There’s yet another Democratic debate tonight, in South Carolina—and health care is expected to be front and center. We’ll let you know tomorrow if there’s anything new to report.  Meanwhile, major news: BIO member Moderna’s coronavirus vaccine is ready for clinical testing. And we’re reading about another major problem for the planet—microplastic—and how biotechnology could help solve it, too. AND we've got a lot of links on everything from the outlook for Grassley-Wyden to biofuel investment. Here are just under 1,000 words/5 minutes.
Read More

Pagination

  • First First page
  • Prev Previous page
  • …
  • 234
  • 235
  • 236
  • …
  • Next Next page
  • Last Last page
Biotechnology Innovation Organization
Explore BIO
Policy
Events
About
Industry Insights
Join Now
BIO PAC
For Members
Member Directory
BIO Policy Committees
Cost-Savings Program
BIO Events
BIO International Convention
BIO Partnering at JPM Week
BIO CEO & Investor Conference
BIO Investor Forum
BIO Patient Health & Advocacy Summit
BIO Intellectual Property Counsels Committee Conference
1201 New York Avenue NW, Suite 1300, Washington, DC, 20005 ・ 202-962-9200
© BIO 2025 All Rights Reserved
Privacy Policy
Terms of Use
Contact BIO